Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psyllium CHD health claim appropriate for foods, supplements, laxatives, P&G tells FDA.

This article was originally published in The Tan Sheet

Executive Summary

PSYLLIUM CHOLESTEROL-LOWERING CLAIM LIMITATION TO FOODS DISCOURAGED BY P&G, maker of the psyllium-containing fiber laxative Metamucil, in Aug. 4 comments to FDA. Procter & Gamble's comments respond to the agency's May 22 proposed rule that would permit use of a health claim based on the association between the consumption of soluble fiber from psyllium and reduced risk of coronary heart disease through the lowering of blood cholesterol levels ("The Tan Sheet" May 26, p. 15). It is not "necessary to restrict the types of products or classes of products" that may bear the claim, P&G maintains; "foods or dietary supplements containing psyllium at the qualifying level should be allowed to used the health claim in labeling and advertising," the company asserts.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS087436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel